lenalidomide has been researched along with Smith-Magenis Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burger, J; Faderl, S; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Strati, P; Tambaro, FP; Wierda, WG | 1 |
| Sun, C; Wiestner, A | 1 |
1 review(s) available for lenalidomide and Smith-Magenis Syndrome
| Article | Year |
|---|---|
Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Humans; Integrin alpha4; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Smith-Magenis Syndrome; Thalidomide; ZAP-70 Protein-Tyrosine Kinase | 2015 |
1 other study(ies) available for lenalidomide and Smith-Magenis Syndrome
| Article | Year |
|---|---|
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Thalidomide; Treatment Outcome | 2014 |